A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab
Gil Awada(Universitair Ziekenhuis Brussel), Bart Neyns(Molecular Oncology (United States)), Pieter‐Jan van Dam(HistoGeneX (Belgium)), Yanina Jansen(Universitair Ziekenhuis Brussel), Anne Rogiers(Centre Hospitalier Universitaire Brugmann), Lennert Hellinckx(Universitair Ziekenhuis Brussel), Marleen Keyaerts(Vrije Universiteit Brussel), Julia Katharina Schwarze(Universitair Ziekenhuis Brussel), Mark Kockx(HistoGeneX (Belgium)), Odrade Gondry(Vrije Universiteit Brussel), Kelly Schats(University of Antwerp), Teofila Seremet(Vrije Universiteit Brussel), Sim Vermeulen(Universitair Ziekenhuis Brussel), Jens Tijtgat(Universitair Ziekenhuis Brussel), Sarah Warren(Nanostring Technologies (United States)), Hendrik Everaert(Universitair Ziekenhuis Brussel)
Cited by 36
Related Papers
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
|New England Journal of Medicine|2012|1k
Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy
|Cell Reports|2019|297